#CBD
Growth Reports on Sales; What’s Ahead for 2019 Sales - (OTC: $HIPH) (OTC:
$EDXC) (OTC: $CANN) (OTC: $MJNA)
Point
Roberts, WA and Delta, BC - August 22, 2019 (Investorideas.com Newswire) Investorideas.com, a leading
investor news resource covering hemp and cannabis stocks releases a snapshot
looking at the recently reported growth in CBD product sales and how this is
now painting a more accurate picture of the CBD market.
In recent news, New York-based Nielsen estimated total
sales of all legalized cannabis, which includes C.B.D. products, reached $8
billion in the United States in 2018.
“As legal
restrictions are loosened, the process of bringing a hemp C.B.D. product to
market, including the leveraging of mainstream distribution channels, could
soon mirror that of other C.P.G. (consumer packaged goods) products,” Nielsen
said. “From over-the-counter medications, to cosmetics, pet care and even
products throughout the traditional food and beverage space, the future
potential of hemp-based C.B.D. could impact billions in C.P.G. sales across
categories.”
CBD has been a
rampant news topic for the past year and has even overshadowed the cannabis
(high THC plant) industry in some regards. However, due to lack of clarity from
the FDA, sales have yet to reach the critical mass many have been anticipating.
This is starting to change as more companies learn to navigate these complex
regulations, product quality and consistency improves and for some, as brand
awareness takes off. Now recent financial results give evidence to an overall
increase in CBD product sales that are finally generating real revenues, both
in the US and abroad.
American Premium Water Corporation (OTC: HIPH) recently announced that it has secured a contract through its
UK subsidiary, which will generate over $833,000 of topline revenue. This is
the largest contract for the Company to date, and puts the Company on a solid
track to exceed its previously issued 2019 revenue guidance of $1 million.
American Premium
Water Corporation CEO, Ryan Fishoff stated, “I’m happy to announce that the
Company has secured its largest contract to date, adding over $833,000 in top
line revenue. The Company is making strides towards becoming the market leader
in premium CBD infused consumer products. We have been making incremental
progress towards bringing our products to market and generating revenue;
shareholders are beginning to see the fruits of management’s labors. There is
still a lot of work to be done; the Company has an ambitious business plan that
it is focused on executing. There is a lot of business in the pipeline that the
Company is working on closing to generate more sales and form partnerships that
will create long-term growth to the Company’s top and bottom line. I am headed
to London this week to ensure that the Company completes the payment process
for this contract so that we can add it to the 2nd quarter filings.”
The contract was
executed in the 2nd quarter of 2019. The payment, which originated from the UK,
had not settled at the time of filing deadline. After consulting with the
Company’s retained accountants, it was determined that it would be in the
Company’s best interests to file 2nd quarter financials to remain compliant
with OTC Markets and the Company will amend the filing upon completion of the
clearing process in accordance with Generally Accepted Accounting Principles
(“GAAP”).
Mr. Fishoff
continued, “Aside from work on this contract and the two-container order that
we announced last week that should be shipping out next month to the UK, the
Company has been focusing on Canyon Create, investing more capital and resources
this quarter into expanding distribution of Vanexxe, which is currently
available on Wal-Mart.com. This ground breaking product fulfills a need for an
affordable and effective cosmetic treatment for unsightly varicose veins, which
before its launch didn’t exist in the marketplace. The Company is also set to
launch its Prickly Pear acne cream, which uses CBD and CBG as its activating
agents. The Company feels this product has the potential to become a market
leader relatively quickly. We’re excited for Canyon and the Company’s other
initiatives that will be picking up steam in the 2nd half of the year. I look
forward to keeping the investor and shareholder community informed as I am able
to update everyone accordingly.”
LALPINA CBD water can
now be purchased online at https://www.singleseed.com/product/lalpina-cbd-water-6-pack/
CBD Unlimited, Inc., formerly known as Endexx Corporation (OTC: EDXC), a provider of innovative
phytonutrient-based food and nutritional products, recently reported year over year revenue growth for its third
quarter of fiscal 2019. For the three months ended June 30, 2019, the Company
generated over $335,000 in sales, which represents an increase of 52% year over
year, and nine months year-to-date $1,252,880 a 108% increase.
“Our third quarter of
fiscal 2019 showcases our accelerated annual growth rate and investment in the
long-term success of CBD Unlimited. Our team continues to innovate and exceed
expectations as we build strong momentum to finish the fiscal year. Earlier, in
December, we forecasted that we would be in 5,000 stores by the end of calendar
2019. We are positioned to surpass this number near term. The company will continue to invest in
inventory, innovation and scalability, delivering and executing the business
plan,” commented CEO & Chairman, Todd Davis. “As we look to the rest of the
year, we expect to continue this growth trajectory as we increase our store
count exponentially. As we scale aggressively, we continue to watch and listen
to the pending FDA suggested guidelines closely. Additionally, we look to
efficiently educate the consumer on our CBD products. We look forward to
executing continued growth for the remainder of fiscal 2019 and on to 2020.”
As mentioned above,
CBD is drawing in a lot of interest, including that of many more THC focused
cannabis companies looking to ride the CBD wave. Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis
company in the United States that launched the world’s first-ever
cannabis-derived nutraceutical products, brands and supply chain, recently announced that the Company has begun manufacturing
operations under an industrial hemp processor license.
This processor
license will allow Medical Marijuana, Inc. to freely store, handle and convert
industrial hemp into a marketable form. This will enable the company to
continue implementing its soil to sale plan, including processing its own raw
material and manufacturing finished goods within the new facility.
“Operating under this
license is a big step for our Company and a great sign for the future of our
domestic operations,” said Medical Marijuana, Inc. CEO, Dr. Stuart Titus. “The
2018 Farm Bill has allowed us to grow our processing and manufacturing
capabilities as well as drive the global supply chain of high-quality hemp.”
General
Cannabis Corp (OTC: CANN), the
comprehensive national resource to the regulated cannabis industry, also recently announced their financial results for the quarter
ended June 30, 2019.
“We have surpassed $1
million in revenue for the fifth consecutive quarter, with a 34% increase in
year-to-date revenue in 2019 compared to 2018,” said Brian Andrews, Chief
Financial Officer of General Cannabis.
“During the first six months of the year, we have increased our focus on
securing significant consulting contracts in emerging markets across the
country and providing wholesale products to new and existing customers. Both
efforts have resulted in significant increases in Operations revenue compared
to the prior year. Security revenues were negatively impacted by customers deciding
to forego guard services and slower than expected growth in California. We continue to explore additional revenue
streams within the Security segment, such as camera monitoring design and
installation, and product transport. In
response to lower revenues from Chiefton, within our Consumer Goods segment,
over the course of the last three months we have eliminated annualized overhead
by approximately $350,000 in order to better match our cost structure to
estimated potential revenues.”
Michael Feinsod,
Chief Executive Officer and Executive Chairman of General Cannabis, stated, “It
was a busy quarter with a focus on our existing businesses while making
significant other operational and business improvements as described in this
release. We expect these steps to reap
benefits over the near term.
“We have recently
opened our new CBD store and e-commerce website, STOA Wellness, which offers a curated collection of quality
products designed for high performance athletes. We strive to offer high quality
products derived from sustainably sourced plants. We believe this sets us apart
and offers our customers a unique experience. We trust these factors will
generate growing Consumer Goods revenue through the remainder of the year.
“In addition to
growing our existing lines of business, we are excited to embark in the coming
months on multiple potential acquisitions we have announced as HB-1090 is
implemented. As of today, we have entered into non-binding term sheets for
approximately 45,000 square feet of cultivation space, a processing facility
and adult use (recreational) dispensaries. Our operating history and Colorado
experience have proven to be strong attractions as we engage with potential
Colorado partners. To date, each of the proposed transactions would keep
existing management teams in place. We
look forward to moving forward with these transactions and integrating these
new teams into our General Cannabis family.
We believe that upon completion, these strategic acquisitions will
create synergistic opportunities that will allow us to leverage our skill sets
to help our customers succeed.”
With more real-time
sales and revenue data coming to the forefront each week, investors and
consumers now have a better assessment of real CBD demand and sales and a more
accurate picture of how the true CBD market is coming into focus. We can expect
to see more sales data over the coming months, especially once the FDA does
release clearer guidelines for the industry, expected later this year.
For investors following
cannabis stocks, Investor Ideas has created a stock
directory of publicly
traded CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana/Hemp Stocks
About Investorideas.com - News that Inspires
Big Investing Ideas
Follow us on Cannabis Social Media
Disclaimer/Disclosure: Our
site does not make recommendations for purchases or sale of stocks, services or
products. Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. This site is currently compensated for news publication and
distribution, social media and marketing, content creation and more. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Contact management and IR of
each company directly regarding specific questions.
Disclosure: this news article featuring HIPH is a paid
for news release on Investorideas.com by a third party Learn more about costs and our services
for articles and podcasts (two thousand)
https://www.investorideas.com/News-Upload/
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Contact Investorideas.com
800-665-0411
No comments:
Post a Comment